Editas tests CRISPR/Cas9 enthusiasm–and a turbulent market–with $122M IPO

John Carroll

Despite facing one of the worst markets for biotech stocks in recent memory, Medicine has taken another big step forward in its quest to raise some big bucks through an IPO. The Cambridge, MA-based biotech noted that it will seek up to $ 122 million through the sale of 6,785,000 shares at $ 16 to $ 18 per share.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS